Background {#Sec1}
==========

Cancer-Associated Retinopathy (CAR) is a paraneoplastic, autoimmune retinopathy characterized by diffuse retinal degeneration. CAR is associated with a variety of cancers, among which small cell lung carcinoma are the most frequent \[[@CR1]\]. Subacute visual loss and visual field constriction are the usual presenting symptoms. The malignancy associated with a CAR can be diagnosed before or after the onset of the ocular manifestations. Because CAR is rare, the descriptions of the disease are based on small series and case reports. As cancer research progresses with improved treatments and increased survival rates, the long term visual outcome of CAR can now be assessed.

The aim of this study was to highlight that in selected cases, ophthalmic findings are consistent enough with the diagnosis of CAR to trigger investigations aimed at detecting a previously unknown malignancy.

Methods {#Sec2}
=======

A retrospective chart review was performed of CAR patients diagnosed at Cochin University Hospital, a uveitis referral center in Paris, France, from 1994 and 2015. The diagnosis of CAR was based on the observation of an intraocular inflammation, the presence of a tubularvisual field (VF) as well as electroretinography (ERG) testing. All patients had a negative family history of retinitis pigmentosa and underwent an extensive workup to exclude other causes of uveitis. The study was performed in accordance with declaration of Helsinki and approved by the ethics committee of the French Society of Ophthalmology (IRB 00008855 Société Française d'Ophtalmologie IRB\#1).

Results {#Sec3}
=======

Four patients met our inclusion criteria: two males and two females, with a median age of 65.5 years (range 58 to 71 years). Presenting complaints were a loss of visual acuity in two cases, VF constriction with photophobia in one case, visual vibrations and floaters in another. The time interval between the first symptoms and the first visit to an ophthalmologist ranges from 2 weeks to 1 month. Subsequently three out of four patients were immediately referred to us and one patient was referred 13 months later.

In all patients, the diagnosis of cancer was unknown at the time of the first ophthalmic visit and none had a significant medical history. The initial ophthalmological presentations are outlined in Table [1](#Tab1){ref-type="table"}. Anterior chamber inflammation was absent in three cases and in the other graded 1+ OU without keratic precipitates or synechiae. Posterior segment inflammation included a 1+ vitreous haze and/or peripheral periphlebitis and one case of bilateral macular edema and papillitis. Visual fields were significantly constricted in all cases with a tubular pattern characterized by limits of the V-1 isopter within the central 30°. Two patients had a fluorescein angiography (FA) in the early course of their disease (patients 1 and 3). Both had periphlebitis and papillitis. Patient 3 had additional macular edema. Patient 4 had an FA 7 years after the onset of the disease: she had no active inflammation but a hyperfluorescence around the vessels due to a window defect caused by atrophy. On ERG, three out of four patients had no identifiable A or B waves from the background noise for all stimuli. Patient 3 presented an undistinguishable rod- and mixed-response; cone-response showed severely reduced amplitudes of the A and B waves with normal implicit times and a conserved morphology. Three patients had a best corrected decimal visual acuity (decimal BCVA) of 0.8 or better in both eyes, with a characteristic pattern of outer retinal atrophy and foveolar sparing on OCT (Fig. [1](#Fig1){ref-type="fig"}). One patient had a decimal BCVA of 0.3 and 0.2 due to a bilateral cystoid macular edema.Table 1Patients' baseline characteristicsCase n°GenderAge-rangeType of cancerTime to diagnosis (months)Decimal BCVA (OD/OS)Anterior Segment inflammationVitritisPeriphlebitisMacular edemaWaxy optic pallorArteriolar narrowingOCTVisual FieldERG1F61--70Uterine Sarcoma20.9/1yesnoyesnoyesyesORAFStubularextinguished2M51--60Lung, small cell10.9/1noyesnonoyesyesORAFStubularextinguished3M71--80Prostate adenocarcinoma250.3/0.2noyesnoyesnonoCMEtubularextinguished4F61--70Lung, small cell10.8/0.8nounknownyesnounknownyesORAFStubularextinguished*BCVA* Best corrected visual acuity, *OCT* Optical coherence tomography, *CME* Cystoid macular edema, *ORAFS* Outer retinal atrophy with foveolar sparingFig. 1Spectral-domain optical coherence tomography (Spectralis, Heidelberg Engineering, Germany) showing the loss of the external limiting membrane, of the inner segment/outer segment junction and of the outer nuclear and plexiform layers with a sparing of the foveal region

A cancer was diagnosed in all four patients, with two cases of small cell lung tumor, one case of prostate carcinoma and one uterine sarcoma. The treatment prescribed to the patients included plasmapheresis and/or systemic corticosteroids and/or azathioprine and/or cyclosporine (Additional file [1](#MOESM1){ref-type="media"}). Patient 3, who presented with a macular edema and grade 1+ vitritis, was initially diagnosed as a case of idiopathic posterior uveitis and treated by periocular or intraocular corticosteroid injections.

Intraocular inflammation subsided in all patients within their follow-up, which ranged from 2 months to 10 years. Patients 3 and 4, for whom the follow-up was the longest, developed a retinitis pigmentosa-like pattern of retinal pigment spicules, diffuse peripheral retinal atrophy and arterial narrowing (Fig. [2](#Fig2){ref-type="fig"}). Within the follow-up OCT imaging showed an outer retinal atrophy with foveal sparing in 3 cases, whereas one patient had a diffuse macular atrophy in the left eye and an irreversible macular edema in the right eye.Fig. 2Fundus photography (Digital Non-Mydriatic Retinal Camera, Canon, USA) of patient four at the last follow-up. Diffuse retinal atrophy combined with arteriolar attenuation, optic disc pallor and pigment deposits are observed

Discussion {#Sec4}
==========

CAR was first defined in 1976 by Sayer et al. who described a clinical triad of photosensitivity, attenuated retinal arterioles, and visual field loss with a ring scotoma in three patients with non-ophthalmic anaplastic tumor \[[@CR2]\]. Subsequently, various case reports have associated this syndrome with other malignancies \[[@CR3], [@CR4]\]. Additional clinical features have been described including extinguished ERG, waxy optic disc pallor \[[@CR5], [@CR6]\], and retinal vasculitis \[[@CR7]\]. Intraocular inflammation as a manifestation of CAR has been previously reported in the literature \[[@CR8]\] and was observed in all of our cases at presentation. The intraocular inflammation can lead to an initial work-up targeted to detect other causes of uveitis, before CAR is diagnosed. Optic disc pallor was already seen at the first examination in two patients for whom the time interval between reported symptoms and diagnosis was short. This might reflect the fact that an underlining subacute inflammation might have remained unnoticed for a long time before the first symptoms. Atrophy of the outer retinal layers with foveal sparing was the most frequent OCT finding in our patients and was a helpful sign in the diagnosis of CAR \[[@CR9]\]. After an initial inflammatory phase, late findings including retinal pigment epithelial mottling and retinal atrophy have been reported and were observed in our two patients with a long follow-up \[[@CR10], [@CR11]\]. In these cases the treatments used were unsuccessful to prevent a diffuse retinal atrophy with a poor visual outcome.

The pathophysiology of CAR remains incompletely understood but molecular mimicry is the generally accepted mechanism. Multiple anti-retinal antibodies have been described in CAR. The most commonly identified auto-antibody is targeted against recoverin. Photoreceptors apoptosis induced by the intravitreal injection of anti-recoverin has been shown in an experimental model \[[@CR12]\]. Recent evidence suggests that the cellular rather the humoral immunity can play a role in the disease \[[@CR13]\]. This would explain the large number of CAR for which auto-antibodies are not detected. The role of the auto-antibodies as an adjunctive test in the diagnosis of CAR is also controversial with an estimated sensitivity of 55.6% at presentation \[[@CR5]\]. The specificity is also low as anti-retinal antibodies can be found in the serum of control patients. \[[@CR14]\] Moreover, the absence of auto-antibodies has a very low negative predictive value and the lack of a standardized methods has led to an important variability in the ability of laboratories to detect retinal auto-antibodies \[[@CR15]\]. Although retinal auto-antibodies were not tested in our patients, their diagnosis of CAR were based on distinctive ophthalmological manifestations and led us with sufficient confidence to search for a malignancy.

Conclusion {#Sec5}
==========

CAR can precede the diagnosis of cancer. When CAR is recognized ophthalmologists can help their patients in referring them for a workup aimed at detecting a primary tumor.
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Additional file 1:Treatment modalities and follow-up data. Description of data: This table describes the treatments and the clinical description at last follow-up. (PDF 43 kb)

BCVA

:   Best-corrected visual acuity

CAR

:   Cancer-associated retinopathy

ERG

:   Electroretinogram

OCT

:   Optical coherence tomography

VF

:   Visual field
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